Hair Loss News

Neosil, Inc. is starting a new Phase 2 clinical hair loss trial in Germany and is looking for volunteers.

The purpose of this study is to evaluate the safety and efficacy of three doses of topical NEOSH101 applied once-daily for 16 weeks in men with thinning hair in the top and center of the scalp (Norwood/Hamilton grades III-IV androgenetic alopecia).

Four equally sized treatment groups (35 men each) will receive either NEOSH101 0.5%, NEOSH101 1.0%, NEOSH101 2.0% or placebo. A 12-week observation period will follow the treatment period.

The criteria for enrolling in the study are men who:

• Are aged 18 to 49 years and in general good health
• Are Norwood/Hamilton grades III - IV androgenetic alopecia, with thinning hair in the vertex area
• Are not currently using any other hair loss treatments
• Have not used minoxidil (Rogaine) for 6 months prior
• Have not used Finasteride (Propecia) for 12 months prior
• Have not used any other trial hair growth products for 6 months prior

The study will be enrolling 140 men and will start in May 2007.

If you live in Germany and are interested in participating the contact details are below.

Elisabeth Rowold, PhD  49 40 606 987 35   elisabeth.rowold@bioskin.de
Bioskin Institute for Dermatological Research and Development GmbH, Hamburg, 20095, Germany